Seek Returns

BIO.B vs. NBIX: Bio-Rad Laboratories vs. Neurocrine Biosciences Stock Comparison

How do Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO.B is classified in Life Sciences Tools & Services while NBIX is classified in Biotechnology.

Company profile comparison for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX)
Profile ItemBIO.BNBIX
NameBio-Rad Laboratories, Inc. Class B Common StockNeurocrine Biosciences, Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization10.49 billion USD16.66 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateSeptember 21, 1999May 23, 1996
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIO.B
NBIX
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX)
MetricBIO.BNBIX
Total Return (1Y)27.69%9.40%
Total Return (3Y, Annualized)9.13%14.12%
Total Return (5Y, Annualized)-12.33%12.61%

Risk Profile

Drawdown History

BIO.B
NBIX
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Neurocrine Biosciences (NBIX) trades around 1.31M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.

Risk profile metrics for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX)
MetricBIO.BNBIX
Volatility (1Y, Annualized)30.96%35.05%
Beta (5Y)1.000.29
Max Drawdown (5Y)-70.74%-42.89%
Avg. Volume (3M)111.31M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIO.B and NBIX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX)
MetricBIO.BNBIX
Sharpe Ratio (1Y)0.740.15
Sortino Ratio (1Y)1.100.22

Profitability

ROE (TTM)

Both Bio-Rad Laboratories (BIO.B) at 14.27% and Neurocrine Biosciences (NBIX) at 20.42% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.42%

Max
109.18%
NBIX
20.42%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Bio-Rad Laboratories (BIO.B) at 39.45% and Neurocrine Biosciences (NBIX) at 18.98% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.98%

NBIX
18.98%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Neurocrine Biosciences (NBIX) at 31.98% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO.B) at 9.46%, which runs around its industry’s norm.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.98%

Max
83.12%
NBIX
31.98%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX)
MetricBIO.BNBIX
ROE (TTM)14.27%20.42%
ROA (TTM)1.50%12.45%
Net Margin (TTM)39.45%18.98%
Operating Margin (TTM)9.46%31.98%
Gross Margin (TTM)52.19%64.67%

Growth

Revenue Growth

Both Bio-Rad Laboratories (BIO.B) at 0.65% and Neurocrine Biosciences (NBIX) at 21.45% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Neurocrine Biosciences (NBIX) reports EPS growth of 41.95%, ranked against its industry; Bio-Rad Laboratories (BIO.B) has no EPS growth figure this period.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX)
MetricBIO.BNBIX
Revenue Growth (YoY)0.65%21.45%
Revenue Growth (3Y CAGR)-2.68%24.32%
EPS Growth (YoY)--41.95%
EPS Growth (3Y CAGR)--44.12%

Financial Strength

Current Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 3.18 keeps current ratio within its industry’s typical mid-range, while Neurocrine Biosciences (NBIX) at 2.04 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NBIX.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.04

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
NBIX
2.04
Min
0.10
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Bio-Rad Laboratories (BIO.B) at 0.18 and Neurocrine Biosciences (NBIX) at 0.12 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.12

Max
1.42
Q3
0.65
Median
0.15
NBIX
0.12
Q1
0.02
Min
0.00
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX)
MetricBIO.BNBIX
Current Ratio (MRQ)3.182.04
Debt / Equity (MRQ)0.180.12
Net Debt / EBITDA-0.73-0.27

Dividends

Dividend Yield (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

NBIX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

NBIX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX)
MetricBIO.BNBIX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO.B) at 10.36 sits in the cheaper P/E ratio quartile, while Neurocrine Biosciences (NBIX) at 24.43 is closer to its industry’s usual earnings multiple — a discount for BIO.B, though growth and earnings durability still matter.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.43

Max
85.34
Q3
43.46
Median
26.69
NBIX
24.43
Q1
13.30
Min
0.07
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Bio-Rad Laboratories (BIO.B) at 4.05 and Neurocrine Biosciences (NBIX) at 4.50 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.50

Max
58.18
Q3
25.77
Median
7.30
NBIX
4.50
Q1
3.01
Min
0.01
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 1.38 sits in the lower P/B ratio quartile against book while Neurocrine Biosciences (NBIX) at 4.30 is valued near its industry’s middle — BIO.B is cheaper on assets, though weigh it against ROE and asset quality.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.30

Max
13.53
Q3
6.54
NBIX
4.30
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Neurocrine Biosciences (NBIX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO.B) and Neurocrine Biosciences (NBIX)
MetricBIO.BNBIX
P/E Ratio (TTM)10.3624.43
P/S Ratio (TTM)4.054.50
P/B Ratio (MRQ)1.384.30
Free Cash Flow Yield (TTM)2.59%6.11%